Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Inflammatory Process Clear all
Completed Phase 2 Interventional

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

NCT00285259
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions
VCL-CB01, Phosphate-buffered Saline (PBS)
Biological · Other
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 22, 2026, 4:29 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

NCT04445220
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Sepsis
Interventions
SBI-101
Biological
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Jul 22, 2026, 4:29 AM EDT
Terminated Phase 3 Interventional

MSCs in COVID-19 ARDS

NCT04371393
View directory record Official record
Conditions
Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions
Remestemcel-L, Placebo
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 22, 2026, 4:29 AM EDT
Completed Phase 3 Interventional

Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients

NCT00001937
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions
FK463, Fluconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 4:29 AM EDT
Recruiting No phase listed Observational

Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study

NCT07425587
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Bluejay Diagnostics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Gainesville, Florida • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 4:29 AM EDT
Terminated Phase 4 Interventional Results available

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

NCT04673175
View directory record Official record
Conditions
Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
Ceftolozane / Tazobactam Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 22, 2026, 4:29 AM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jul 22, 2026, 4:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02759731
View directory record Official record
Conditions
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
Interventions
Baricitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 22, 2026, 4:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

NCT05531786
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pacritinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 4:29 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT06255028
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Biological · Drug
Lead sponsor
Century Therapeutics, Inc.
Industry
Eligibility
17 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 4:29 AM EDT
Not listed No phase listed Observational

Study of Treatment's Echocardiographic Mechanisms

NCT03913403
View directory record Official record
Conditions
Sepsis
Interventions
ECHO, Blood Draw
Procedure
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Boston, Massachusetts • The Bronx, New York • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Jul 22, 2026, 4:29 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers in Infection

NCT02545478
View directory record Official record
Conditions
Sepsis, Infection, Inflammation
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 4:29 AM EDT
Not listed No phase listed Observational

Translational Approaches to Septic Cardiomyopathy

NCT03252613
View directory record Official record
Conditions
Cardiomyopathies, Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Samuel Brown
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Stanford, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Jul 22, 2026, 4:29 AM EDT
Completed No phase listed Observational

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies

NCT04710212
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Acute, Neutropenia, Bloodstream Infection
Interventions
No intervention.
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
San Francisco, California • Nutley, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Protective Effects of Delayed Cord Clamping in Very Low Birth Weight (VLBW) Infants

NCT00818220
View directory record Official record
Conditions
Intraventricular Hemorrhage, Sepsis
Interventions
delayed umbilical cord clamping, Immediate cord clamping
Procedure · Other
Lead sponsor
University of Rhode Island
Other
Eligibility
Not listed
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Jul 22, 2026, 4:29 AM EDT
Completed Phase 4 Interventional

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

NCT00067730
View directory record Official record
Conditions
Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection
Interventions
Drotrecogin Alfa (activated)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
5
States / cities
Denver, Colorado • Iowa City, Iowa • Manhassaet, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Jul 22, 2026, 4:29 AM EDT
Active, not recruiting Phase 2 Interventional

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

NCT05579639
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
Xylitol, Placebo
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Months to 25 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 4:29 AM EDT
Not listed Phase 2 Interventional

MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

NCT04533464
View directory record Official record
Conditions
Trauma, Adult Stem Cells
Interventions
MultiStem, Placebo
Biological
Lead sponsor
Healios K.K.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Jul 22, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions

NCT03938324
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

NCT01351805
View directory record Official record
Conditions
Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis
Interventions
Fish Oil, Vitamin D, placebo pill
Drug · Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 22, 2026, 4:29 AM EDT